PI3K/Akt Pathway

Overview

The phosphoinositide 3-kinase (PI3K)/Akt pathway is one of the most frequently activated signaling cascades in human biology. It serves as a central node connecting extracellular growth signals to intracellular decisions about cell survival, growth, proliferation, metabolism, and motility. Nearly every growth factor receptor, many cytokine receptors, and the integrin-FAK adhesion system feed into PI3K/Akt, making it a convergence point for diverse upstream inputs.

For peptide research, the PI3K/Akt pathway is significant because it sits downstream of virtually every growth factor and receptor system that bioactive peptides modulate. IGF-1 (from the growth hormone axis), VEGF (from VEGF signaling), FAK (from focal adhesion signaling), and numerous cytokine receptors all activate PI3K/Akt. Understanding this pathway provides mechanistic context for the anti-apoptotic, pro-survival, and growth-promoting effects attributed to many research peptides.

How It Works

PI3K: The Initiating Kinase

Phosphoinositide 3-kinases are a family of lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositols in cell membranes. The family is divided into three classes, but Class I PI3Ks are the most relevant to growth factor signaling:

Class IA PI3Ks — Heterodimers consisting of:

• A catalytic subunit (p110α, p110β, or p110δ)
• A regulatory subunit (p85α, p55α, p50α, p85β, or p55γ)

The regulatory p85 subunit contains SH2 domains that bind to phosphorylated tyrosine residues on activated receptor tyrosine kinases (RTKs), growth factor receptor substrates (IRS-1/2), or adaptor proteins. This binding relieves p85-mediated inhibition of the p110 catalytic subunit and recruits the enzyme to the plasma membrane where its lipid substrates reside.

The PIP3 Second Messenger

Activated PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 is a membrane-bound lipid second messenger that recruits proteins containing pleckstrin homology (PH) domains to the plasma membrane, most importantly Akt and PDK1.

PTEN (phosphatase and tensin homolog) is the primary negative regulator of PI3K signaling. PTEN dephosphorylates PIP3 back to PIP2, directly opposing PI3K activity. PTEN is one of the most frequently mutated or deleted tumor suppressors in human cancer, underscoring the importance of keeping PI3K/Akt signaling under control.

Akt Activation: A Two-Step Process

Akt (also called protein kinase B, PKB) exists in three isoforms (Akt1, Akt2, Akt3) with partially overlapping functions. Akt1 is ubiquitously expressed and the best characterized.

Akt activation requires phosphorylation at two key residues:

1. Threonine 308 (T308) — Phosphorylated by PDK1 (phosphoinositide-dependent kinase 1). Both PDK1 and Akt are recruited to the membrane by PIP3 via their PH domains, bringing them into proximity.

2. Serine 473 (S473) — Phosphorylated by mTORC2 (the mTOR complex 2). This creates a positive feedback loop: PI3K/Akt activates mTORC1, while mTORC2 completes Akt activation.

Fully activated (dual-phosphorylated) Akt detaches from the membrane and phosphorylates a wide range of cytoplasmic and nuclear substrates.

Downstream Targets of Akt

Akt phosphorylates over 100 known substrates, regulating virtually every aspect of cell biology:

Cell survival (anti-apoptotic)

• BAD — Akt phosphorylates the pro-apoptotic BH3-only protein BAD, causing its sequestration by 14-3-3 proteins and preventing it from inhibiting anti-apoptotic Bcl-2/Bcl-xL
• Caspase-9 — Direct Akt phosphorylation inhibits caspase-9 activity
• FOXO transcription factors — Akt phosphorylates FOXO1/3/4, causing their nuclear exclusion and preventing transcription of pro-apoptotic genes (Bim, FasL, TRAIL)
• MDM2 — Akt phosphorylates MDM2, promoting p53 degradation

Cell growth and proliferation

• TSC2 — Akt phosphorylates and inhibits TSC2, activating the mTOR pathway for protein synthesis and cell growth
• GSK-3β — Akt phosphorylates and inhibits GSK-3β, stabilizing cyclin D1 and β-catenin to promote cell cycle progression
• p21/p27 — Akt phosphorylation of these CDK inhibitors promotes their cytoplasmic sequestration

Metabolism

• GSK-3β inhibition — Promotes glycogen synthesis
• AS160 — Akt phosphorylates AS160, stimulating GLUT4 vesicle translocation and glucose uptake (insulin signaling)
• FOXO inhibition — Suppresses gluconeogenic gene expression in the liver

Angiogenesis

• eNOS — Akt phosphorylates endothelial nitric oxide synthase at S1177, activating NO production. This links PI3K/Akt to VEGF signaling-driven angiogenesis via the nitric oxide system.

Inflammation

• IKK — Akt can activate the IKK complex, linking to the NF-kB pathway

Key Components

Role in Peptide Research

Growth Hormone Axis Peptides

IGF-1, the downstream effector of the growth hormone axis, is one of the most potent activators of PI3K/Akt signaling. Peptides that stimulate GH release (CJC-1295, ipamorelin, GHRP-6, sermorelin) therefore increase PI3K/Akt activation indirectly through elevated IGF-1. The anti-apoptotic and anabolic effects of GH secretagogues are substantially mediated through this pathway.

BPC-157

BPC-157 activates PI3K/Akt signaling through multiple upstream mechanisms. Its activation of FAK (Y397 phosphorylation) directly recruits PI3K. Its upregulation of VEGFR2 also activates PI3K/Akt in endothelial cells. And its activation of the Egr-1 → Akt1 signaling cascade (documented within minutes of wound induction) positions PI3K/Akt as a rapid mediator of BPC-157's cytoprotective and pro-survival effects.

TB-500

TB-500 (thymosin beta-4) has been shown to activate Akt signaling in cardiac cells and endothelial cells, contributing to its documented cardioprotective and pro-survival effects in ischemic injury models.

Humanin

Humanin, a mitochondrial-derived peptide, activates PI3K/Akt through the CNTFR/WSX-1/gp130 receptor complex and through direct binding to IGFBP-3. Akt activation mediates humanin's neuroprotective effects against amyloid-beta toxicity and other cellular stresses.

SS-31 (Elamipretide)

While SS-31 acts primarily on mitochondrial function, its effects on cellular survival during ischemia-reperfusion involve PI3K/Akt pathway activation as part of the reperfusion injury salvage kinase (RISK) pathway.

Clinical Significance

• Cancer — The PI3K/Akt pathway is the most frequently altered signaling pathway in human cancer. PIK3CA (encoding p110α) is among the most commonly mutated oncogenes, and PTEN is among the most commonly deleted tumor suppressors. Numerous PI3K inhibitors (alpelisib, idelalisib, copanlisib) and Akt inhibitors (capivasertib) are approved or in clinical development.
• Diabetes — Insulin signals through PI3K/Akt to promote glucose uptake via GLUT4 translocation. Impaired PI3K/Akt signaling in muscle and adipose tissue is a central feature of insulin resistance and type 2 diabetes.
• Cardiac protection — The RISK (reperfusion injury salvage kinase) pathway, which includes PI3K/Akt, is cardioprotective during ischemia-reperfusion. Therapeutic strategies to activate this pathway during cardiac interventions are under investigation.
• Neurodegeneration — Reduced PI3K/Akt/FOXO signaling contributes to neuronal vulnerability in Alzheimer's and Parkinson's disease. The neuroprotective effects of several peptides are mediated through Akt activation.
• Immune function — PI3K isoforms play specific roles in immune cell function. PI3Kδ and PI3Kγ are preferentially expressed in leukocytes, and their inhibitors are used in hematologic malignancies.

Related Topics

• mTOR Pathway — Primary downstream target of Akt for cell growth and protein synthesis
• VEGF Signaling Pathway — VEGFR2 activates PI3K/Akt in endothelial cells
• FAK-Paxillin Pathway — FAK Y397 recruits PI3K for survival signaling
• Nitric Oxide System — Akt phosphorylates eNOS for NO production
• Growth Hormone Axis — IGF-1 is a major PI3K/Akt activator
• NF-kB Pathway — Akt can activate NF-kB through IKK phosphorylation